Study: Del 2018, Journal of the American Academy of Dermatology
Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma
Citation
Del Rosario E, Florez-Pollack S, Zapata L et al (2018). Journal of the American Academy of Dermatology. PubMed id 28987494.
Cards that cite this study (1)
Each card gives its own wording for who was tested, how and what was found.
- Melasma Tier B moderate
B 44 people with moderate-to-severe melasma, mostly Hispanic women, single centre (n=44)
Randomised, placebo-controlled trial of oral tranexamic acid for 3 months, with sunscreen.
Melasma severity score fell 49% on tranexamic acid and 18% on placebo at 3 months; 3 months after stopping the gap had narrowed (26% against 19% from baseline). No serious adverse events.
As recorded in this card: Del Rosario E, Florez-Pollack S, Zapata L et al (2018), Journal of the American Academy of Dermatology, [primary]
Note: Predominantly Hispanic women, per its own limitations line. Tranexamic acid is a prescription medicine.
This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence. All studies.